Form 4: Soligenix Director Diane Parks Granted Stock Options

Soligenix, Inc. Director Diane L. Parks was granted 17,647 stock options with an exercise price of $1.70, vesting quarterly over one year.

Summary

• Diane L. Parks, a Director of Soligenix, Inc. (SNGX), was granted 17,647 stock options.
• The options have an exercise price of $1.70 per share.
• The grant date for these options was June 20, 2025.
• The options will vest ratably over four quarters, starting September 20, 2025, and concluding June 20, 2026.
• The options have an expiration date of June 20, 2035.
• Following this transaction, Ms. Parks beneficially owns 17,647 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns management's interests with shareholders and is a standard compensation practice. While it introduces potential future dilution, it's a common and expected part of corporate governance and incentive structures.

Positives

• The grant of stock options aligns the interests of Director Diane L. Parks with those of shareholders, as the options gain value if the company's stock price increases above the exercise price of $1.70.
• This is a standard form of compensation for directors, indicating continued commitment and incentivization.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised, although this is a common practice for equity compensation.

Risks

• The value of the stock options is subject to the future market price of Soligenix, Inc. common stock; if the stock price does not exceed the $1.70 exercise price, the options may expire worthless.
• Future stock price volatility could impact the realized value of these options.

Future Outlook

The stock options granted to Director Diane L. Parks are scheduled to vest ratably over four quarters, commencing on September 20, 2025, and concluding on June 20, 2026, providing a future incentive structure.

Industry Context

This Form 4 filing details an individual insider transaction, specifically a stock option grant, which is a common practice in the biotechnology and pharmaceutical industries for executive and director compensation to align interests with long-term company performance.

Comparison to Industry Standards

• NA

Related Party Transactions

• The stock option grant to Director Diane L. Parks is a transaction between the company and a related party (an insider), which is a common form of equity compensation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned for general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• The stock options will vest ratably on September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.
• Diane L. Parks may exercise the vested options at any time before their expiration on June 20, 2035, subject to company policies and insider trading regulations.

Key Dates

Keywords

Soligenix, SNGX, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, Derivative Securities